Research Analysts Offer Predictions for Rezolute Q1 Earnings

Rezolute, Inc. (NASDAQ:RZLT) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Rezolute in a report released on Friday, February 13th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings per share of ($0.08) for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.11) EPS and FY2030 earnings at $0.35 EPS.

Several other research analysts also recently commented on the company. JMP Securities set a $17.00 target price on Rezolute in a research note on Wednesday, October 29th. Citizens Jmp cut shares of Rezolute from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 11th. Wall Street Zen downgraded shares of Rezolute from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Craig Hallum lowered shares of Rezolute from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a research report on Thursday, December 11th. Finally, Wedbush upped their price target on shares of Rezolute to $2.00 and gave the stock a “neutral” rating in a report on Thursday, January 8th. Five investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $8.67.

Rezolute Stock Performance

Shares of RZLT stock opened at $3.84 on Monday. Rezolute has a fifty-two week low of $1.07 and a fifty-two week high of $11.46. The stock’s fifty day moving average price is $3.01 and its two-hundred day moving average price is $6.51. The company has a market cap of $367.49 million, a PE ratio of -4.13 and a beta of 0.46.

Rezolute (NASDAQ:RZLT) last released its earnings results on Thursday, February 12th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.06).

Institutional Trading of Rezolute

A number of institutional investors have recently bought and sold shares of the company. Federated Hermes Inc. lifted its position in Rezolute by 24.4% in the 2nd quarter. Federated Hermes Inc. now owns 14,034,712 shares of the company’s stock valued at $62,595,000 after acquiring an additional 2,755,385 shares in the last quarter. Stonepine Capital Management LLC purchased a new stake in shares of Rezolute in the second quarter worth approximately $977,000. Geode Capital Management LLC lifted its holdings in shares of Rezolute by 201.7% in the second quarter. Geode Capital Management LLC now owns 1,711,043 shares of the company’s stock valued at $7,633,000 after purchasing an additional 1,143,834 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Rezolute by 56.4% in the second quarter. Marshall Wace LLP now owns 2,886,481 shares of the company’s stock valued at $12,874,000 after purchasing an additional 1,041,234 shares in the last quarter. Finally, Affinity Asset Advisors LLC boosted its position in shares of Rezolute by 29.4% during the second quarter. Affinity Asset Advisors LLC now owns 2,200,000 shares of the company’s stock valued at $9,812,000 after buying an additional 500,000 shares during the last quarter. Institutional investors own 82.97% of the company’s stock.

Insider Buying and Selling at Rezolute

In related news, CFO Daron Evans purchased 40,000 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was bought at an average price of $1.77 per share, with a total value of $70,800.00. Following the completion of the purchase, the chief financial officer owned 415,900 shares in the company, valued at approximately $736,143. This represents a 10.64% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Nevan C. Elam bought 32,000 shares of Rezolute stock in a transaction that occurred on Monday, December 15th. The stock was bought at an average price of $1.59 per share, for a total transaction of $50,880.00. Following the completion of the acquisition, the chief executive officer directly owned 641,119 shares of the company’s stock, valued at $1,019,379.21. The trade was a 5.25% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders purchased 89,100 shares of company stock worth $150,232. 14.78% of the stock is currently owned by insiders.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.